12,372 trials
Supraventricular Tachycardia
Primary: Incidence of Recurrent Supraventricular Tachycardia (SVT) Requiring Medical Intervention to Terminate the Episode. — 12; 18 percentage of participants
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
Acne Scarring of the Face
Primary: Evaluator Live Acne Scarring Assessment Responders — 64; 46 Participants — p=0.0109
Haemophilus Influenzae Type b
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0…
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean — 1.14; 0.92; 0.90; 0.79 Exacerbations per participant per year — p=0.040
Non-Small Cell Lung Carcinoma
Primary: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment — 33; 25 percentage of participants…
Myocardial Infarction · Chest Pain
Primary: Hospital Time to Treatment for Patients With Unstable Angina/Non-STEMI — 23; 31 minutes
Patients Receiving Fractionated Stereotactic Radiotherapy · for Brain Tumors
Primary: Distance From Ideal to Center of GTC Frame and BrainLab Thermoplastic Mask With Respect to Average and Variability — 2.00; 3.17 millimeters
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean — 1.05; 0.92; 0.70; 0.90 Exacerbations per participant per year — p=0.181
Hepatitis B
Primary: Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48 — 79; 18; 149; 109 Participants — p=<0.0001
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours (h) Post-dose at Day 168 — -0.012; 0.034; 0.029; 0.173 Liters — p=0.085
Urea Cycle Disorders
Primary: Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug) — 33 participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168 — 0.026; 0.080; 0.129; 0.218 Liters — p=0.040
Lupus Erythematosus, Systemic
Primary: Change in Mean-Mean Common Carotid IMT (CIMT) — 0.0010; 0.0024 mm